Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Goldman Sachs Downgrades Cytokinetics to Neutral, Lowers Price Target to $60

Author: Benzinga Newsdesk | August 13, 2024 05:13am

Goldman Sachs analyst Paul Choi downgrades Cytokinetics (NASDAQ:CYTK) from Buy to Neutral and lowers the price target from $85 to $60.

Posted In: CYTK